@article{85e33769bb2445a1aeabba472308b557,
title = "Advancing stiffness measurement in rheumatic disease: Report from the stiffness special interest group at OMERACT 2018",
abstract = "Objective. To improve measurement of stiffness in rheumatic disease. Methods. Data presented included (1) 2 qualitative projects, (2) the rheumatoid arthritis (RA) stiffness patient-reported outcome measure (RAST), and (3) 3 items assessing stiffness severity, duration, and interference. Results. Stiffness is multidimensional and includes aspects of stiffness experience such as duration, severity, and effect. Stiffness items showed construct validity in RA. Further efforts are required to develop an instrument that will be taken through the Outcome Measures in Rheumatology (OMERACT) Filter 2.1 for instrument selection. Conclusion. The research agenda for the group includes domain content voting for individual diseases, and development of stiffness item banks and disease-specific short forms.",
keywords = "Morning stiffness, Omeract, Outcome assessment",
author = "Craig, {E. T.} and Orbai, {A. M.} and S. Mackie and Bartlett, {S. J.} and Bingham, {C. O.} and S. Goodman and C. Hill and R. Holt and A. Leong and C. Karyekar and Leung, {Y. Y.} and P. Richards and S. Halls",
note = "Funding Information: The authors acknowledge all OMERACT 2016 Stiffness Special Interest Group participants for their contributions. A travel scholarship from Janssen supported the fellow attendance to the OMERACT conference. A research grant from Horizon pharma provided funding in part for statistical analysis. All analysis was conducted by investigators. We thank Jennifer Horonjeff, PhD, for her collaboration with the SIG. Funding Information: From the Johns Hopkins University School of Medicine, Baltimore, Maryland; Department of Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, New York; Horizon Pharma Inc., Lake Forest; College of Pharmacy, University of Illinois, Chicago, Illinois; Healthy Motivation, Bone and Joint Decade Global Alliance for Musculoskeletal Health, Santa Barbara, California; Janssen Scientific Affairs LLC, Horsham, Pennsylvania, USA; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; and Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds; University of Bristol; University of the West of England, Bristol, Bristol, UK; McGill University, Montreal, Quebec, Canada; Division of Medicine, The University of Adelaide, Adelaide; Rheumatology Unit, The Queen Elizabeth Hospital, Woodville, Australia; Singapore General Hospital, Duke–National University of Singapore (NUS) Medical School, Singapore. AMO is a Jerome L. Greene Foundation Scholar and is supported in part by a research grant from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health (NIH) under award number P30-AR070254 (Core B), a Rheumatology Research Foundation Scientist Development award, and a Staurulakis Family Discovery award. Work from the US Cohort was supported by the NIAMS of the NIH under award numbers [P30-AR070254 Core B] and [P30-AR053503 Core D] and Patient Centered Outcomes Research Institute (PCORI) Pilot Project Award number [IP2-PI000737], and the Camille Julia Morgan Arthritis Research and Education Fund. All statements in this report including its conclusions are the opinions of the authors and do not necessarily reflect those of PCORI, its board of governors, or its methodology committee, or of NIH or NIAMS. RH is an employee of Horizon Pharma LLC. CK is an employee of Janssen Scientific Affairs LLC. Publisher Copyright: The Journal of Rheumatology Copyright {\textcopyright} 2019. All rights reserved.",
year = "2019",
doi = "10.3899/jrheum.181074",
language = "English (US)",
volume = "46",
pages = "1374--1378",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "10",
}